Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

AbbVie challenges J&J with Skyrizi PsA submission, says GlobalData

In early April, AbbVie announced its submission to the US FDA for its selective interleukin (IL)-23 inhibitor, Skyrizi (risankizumab), for the indication of psoriatic arthritis (PsA). If approved, Skyrizi would be the second inhibitor available for the disease, however, Skyrizi is entering an increasingly crowded and competitive field with numerous existing branded agents and biosimilars […]
Read more

Pharma industry investments in blockchain decreased in 2020 as organizations shifted priorities during COVID-19 pandemic, says GlobalData

Despite considerable improvements that blockchain could bring to the pharmaceutical sector, this technology-related revolution has not quite happened yet. While COVID-19 accelerated digital transformation in the pharmaceutical industry, blockchain witnessed a setback in 2020, says GlobalData, a leading data and analytics company. GlobalData’s survey found that in 2020 investments in blockchain decreased by 6% compared […]
Read more

Chinese COVID-19 vaccines supply remains crucial for developing nations irrespective of real-world data, says GlobalData

Beijing-based pharmaceutical company Sinovac Biotech’s CoronaVac vaccine was recently found to be 49.6% effective in real-world data from Brazil. However, considering the global demand for COVID-19 vaccines and the supply-demand gaps, Chinese vaccines remain crucial for developing nations’ vaccination programs irrespective of real-world data, says GlobalData, a leading data analytics and research company. China has […]
Read more

Monoclonal antibodies targeted against COVID-19 have high potential, but their efficacy against emerging variants remains muddled, says GlobalData

The emergence of new SARS-CoV-2 variants have been detected in over 40 countries and are disrupting drug development worldwide. The prevalence of these more transmissible strains is growing fast and may require adjustments to current therapies to ensure they retain clinical efficacy, says GlobalData, a leading data and analytics company. Nancy Jaser, PharmD/MBA, Pharma Analyst […]
Read more

SalioGen therapeutics’ non-viral gene therapy platform may potentially expand access to novel rare disease therapeutics, says GlobalData

In March 2021, SalioGen therapeutics raised $20m to support the preclinical validation of its non-viral gene therapy platform, exact DNA integration technology. The development of non-viral gene therapy manufacturing platforms will likely increase patient access to gene therapy and improve the cost-to-benefit ratio, says GlobalData, a leading data and analytics company. SalioGen has engineered a […]
Read more

Gemtesa is a welcome entrant to US overactive bladder market as it addresses need for safer therapies, says GlobalData

The commercial launch of Urovant Sciences’ first product, Gemtesa (vibegron), a beta 3 adrenergic receptor agonist in the US, addresses overactive bladder (OAB) symptoms by increasing bladder capacity and an unmet need for alternative, safer therapies for US patients, says GlobalData, a leading data and analytics company. In recent years, Urovant has become established as […]
Read more

Sputnik V to face stiff competition in India despite better efficacy but will help ramp up vaccination drive, says GlobalData

With the Sputnik V vaccine’s recent approval, India now has three vaccines authorized for COVID-19 treatment. However, despite better efficacy over Serum Institute of India/ AstraZeneca’s Covishield and Bharat Biotech’s Covaxin, Sputnik V will face stiff competition in India, says GlobalData, a leading data analytics and research company. Dr Reddy’s Laboratories (DRL) will receive Sputnik […]
Read more

Amgen’s $1.9bn bet on Five Prime Therapeutics will require more than one label for bemarituzumab to pay off, says GlobalData

Following today’s news (16 April) that Amgen has completed its planned acquisition of Five Prime Therapeutics for $1.9bn; Sakis Paliouras, PhD, Senior Oncology & Hematology Analyst at GlobalData, a leading data and analytics company, offers his view: “Amgen’s main interest in Five Prime’s pipeline was the lead, first-in-class anti-FGFR2b inhibitor bemarituzumab tested in gastric (GC) […]
Read more

Chinese checkpoint inhibitors may drive down drug prices, says GlobalData

Chinese domestic ICI brands poised for approvals across multiple oncology indications International brands seeking access in China should balance diminishing drug prices with the opportunity to target enormous patient pool Immune checkpoint inhibitors (ICIs) and their introduction into the treatment paradigm of multiple oncology indications has arguably been the largest transformative force in the treatment […]
Read more
1 … 64 65 66 67 68 … 108